<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="mpv17-mtdep" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">mpv17-mtdep</book-part-id>
      <title-group>
        <title><italic toggle="yes">MPV17</italic>-Related Hepatocerebral Mitochondrial DNA Depletion Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>El-Hattab</surname>
            <given-names>Ayman W</given-names>
          </name>
          <degrees>MD, FAAP, FACMG</degrees>
          <aff>Division of Clinical Genetics and Metabolic Disorders<break/>Pediatric Department<break/>Tawam Hospital<break/>Al-Ain, United Arab Emirates</aff>
          <email>elhattabaw@yahoo.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Scaglia</surname>
            <given-names>Fernando</given-names>
          </name>
          <degrees>MD, FAAP, FACMG</degrees>
          <aff>Associate Professor, Department of Molecular and Human Genetics<break/>Baylor College of Medicine<break/>Houston, Texas</aff>
          <email>fscaglia@bcm.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Craigen</surname>
            <given-names>William J</given-names>
          </name>
          <degrees>MD, PhD, FACMG</degrees>
          <aff>Professor, Department of Molecular and Human Genetics<break/>Professor, Department of Pediatrics<break/>Director, Metabolic Clinic<break/>Medical Director, Mitochondrial Diagnostic Laboratory<break/>BCM Medical Genetics Laboratories<break/>Baylor College of Medicine<break/>Houston, Texas</aff>
          <email>wcraigen@bcm.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wong</surname>
            <given-names>Lee-Jun C</given-names>
          </name>
          <degrees>PhD, FACMG</degrees>
          <aff>Professor, Department of Molecular and Human Genetics<break/>Director, Mitochondrial Diagnostic Laboratory<break/>BCM Medical Genetics Laboratories<break/>Baylor College of Medicine<break/>Houston, Texas</aff>
          <email>ljwong@bcm.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>17</day>
          <month>5</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="mpph" document-type="chapter">MPPH Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="maps" document-type="chapter"><italic toggle="yes">MUTYH</italic>-Associated Polyposis</related-object>
      <abstract id="mpv17-mtdep.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">MPV17</italic>-related hepatocerebral mitochondrial DNA (mtDNA) depletion syndrome is characterized by infantile-onset liver dysfunction that typically progresses to liver failure; neurologic involvement (developmental delay, hypotonia, and muscle weakness in the majority; ataxia, seizures, and motor and sensory peripheral neuropathy in some); failure to thrive; and metabolic derangements including lactic acidosis and hypoglycemic crises. Less frequent manifestations include renal tubulopathy, hypoparathyroidism, gastrointestinal dysmotility, and corneal anesthesia. Progressive liver disease often leads to death in infancy or early childhood. Hepatocellular carcinoma has been reported.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Mitochondrial DNA content is severely reduced in liver tissue (&#x0003c;20% of controls) and muscle tissue (&#x0003c;30% of controls). Molecular genetic testing of <italic toggle="yes">MPV17</italic> detects biallelic pathogenic variants in most affected children.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Ideally management is by a multidisciplinary team including specialists in hepatology, neurology, nutrition, clinical genetics, and child development. Nutritional support should be provided by a dietitian experienced in managing children with liver diseases; prevention of hypoglycemia requires frequent feeds and uncooked cornstarch (1-2 grams/kg/dose). Although liver transplantation remains the only treatment option for liver failure, it is controversial because of the multisystem involvement in this disorder.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Prevent nutritional deficiencies (e.g., of fat-soluble vitamins) by ensuring adequate intake.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitor: liver function to assess progression of liver disease; serum alpha fetoprotein (AFP) concentration and hepatic ultrasound examination for evidence of hepatocellular carcinoma; development, neurologic status, and nutritional status.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Prolonged fasting.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="mpv17-mtdep.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="mpv17-mtdep.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_mpv17-mtdep.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">MPV17</italic>-Related Hepatocerebral Mitochondrial DNA Depletion Syndrome: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_mpv17-mtdep.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Navajo neurohepatopathy</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="mpv17-mtdep.Diagnosis">
        <title>Diagnosis</title>
        <sec id="mpv17-mtdep.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">MPV17</italic>-related hepatocerebral mitochondrial DNA (mtDNA) depletion syndrome should be suspected in infants with a combination of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hepatic manifestations including elevated transaminases, jaundice, cholestasis, hepatomegaly, cirrhosis, and liver failure</p>
            </list-item>
            <list-item>
              <p>Neurologic manifestations including developmental delay, hypotonia, muscle weakness, ataxia, motor and sensory peripheral neuropathy, and leukoencephalopathy by brain MRI [<xref ref-type="bibr" rid="mpv17-mtdep.REF.navarrosastre.2008.234">Navarro-Sastre et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2008.1108">Spinazzola et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p>Failure to thrive</p>
            </list-item>
            <list-item>
              <p>Metabolic derangements including lactic acidosis and severe hypoglycemic crises in early infancy</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpv17-mtdep.Testing">
          <title>Testing</title>
          <p><bold>Mitochondrial DNA (mtDNA)</bold>
<bold>content (copy number) analysis</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>Mitochondrial DNA content is severely and consistently reduced in liver tissue (&#x0003c;20% of tissue- and age-matched controls).</p>
            </list-item>
            <list-item>
              <p>Mitochondrial DNA content can also be reduced in muscle tissue (typically &#x0003c;30% of tissue- and age-matched controls).</p>
            </list-item>
          </list>
          <p>Note: Mitochondrial DNA copy number values in blood cells are not a reliable indicator of mtDNA depletion [<xref ref-type="bibr" rid="mpv17-mtdep.REF.dimmock.2010.1119">Dimmock et al 2010</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
          <p><bold>Electron transport chain (ETC) activity.</bold> ETC activity assays in liver and muscle tissue of affected individuals typically show decreased activity of multiple complexes with complex I or I+III being the most affected. Similar to the findings of mtDNA content, the liver ETC activities are usually more reduced than those of muscle tissue [<xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
          <sec id="mpv17-mtdep.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">MPV17</italic>, which encodes for a mitochondrial inner membrane protein, is the only gene in which pathogenic variants cause <italic toggle="yes">MPV17</italic>-related hepatocerebral mitochondrial DNA depletion syndrome.</p>
            <table-wrap id="mpv17-mtdep.T.summary_of_molecular_genet" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">MPV17</italic>-Related Hepatocerebral mtDNA Depletion Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">MPV17</italic>
                    </td>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28/31 (90%)&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
                    <td headers="hd_h_mpv17-mtdep.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2/31 (6%)&#x000a0;<sup>7</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="mpv17-mtdep.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="mpv17-mtdep" object-id="mpv17-mtdep.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="mpv17-mtdep.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="mpv17-mtdep.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="mpv17-mtdep.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="mpv17-mtdep.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="mpv17-mtdep.TF.1.5">
                  <label>5. </label>
                  <p>Sequencing of all coding exons and the flanking intronic regions identified homozygous or compound heterozygous variants in 28 of 31 affected individuals [<xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.merkle.2012.e34">Merkle et al 2012</xref>].</p>
                </fn>
                <fn id="mpv17-mtdep.TF.1.6">
                  <label>6. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="mpv17-mtdep.TF.1.7">
                  <label>7. </label>
                  <p>A 1.57-kb deletion spanning exon 8 has been reported in two affected individuals [<xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="mpv17-mtdep.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> As a part of the workup of unexplained infantile liver dysfunction, the liver biopsy that is obtained for pathologic examination should also undergo mtDNA content analysis.</p>
          <p>The identification of severely reduced mtDNA copy number should prompt further evaluation that includes molecular genetic testing of <italic toggle="yes">MPV17</italic>:</p>
          <list list-type="bullet">
            <list-item>
              <p>If homozygous or compound heterozygous pathogenic variants are identified by sequence analysis, the diagnosis is confirmed. Molecular genetic testing of both parents is needed to confirm their carrier status and the phase of the pathogenic variants in the proband.</p>
            </list-item>
            <list-item>
              <p>If one or no pathogenic variants are detected by sequence analysis, or the parents&#x02019; carrier status cannot be confirmed, deletion/duplication analysis is recommended.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="mpv17-mtdep.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="mpv17-mtdep.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome, an infantile-onset disorder, can present with a spectrum of combined hepatic, neurologic, and metabolic manifestations. To date, molecularly confirmed <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome has been reported in 31 individuals [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2006.570">Spinazzola et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.wong.2007.1218">Wong et al 2007</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.navarrosastre.2008.234">Navarro-Sastre et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2008.1108">Spinazzola et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.kaji.2009.292">Kaji et al 2009</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.parini.2009.215">Parini et al 2009</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.merkle.2012.e34">Merkle et al 2012</xref>].</p>
          <p>Of note, among the 31 confirmed cases are individuals with Navajo neurohepatopathy who were found to have homozygous <xref ref-type="table" rid="mpv17-mtdep.T.mpv17_pathogenic_variants">p.Arg50Gln</xref> pathogenic variants in <italic toggle="yes">MPV17</italic> [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>]. Navajo neurohepatopathy, a disorder prevalent in the Native American Navajo population, has the manifestations of <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome as well as painless fractures, acral mutilation, and corneal anesthesia, ulceration, and scarring.</p>
          <p>The clinical manifestations of <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome discussed here are based on the phenotype observed in those 31 individuals and summarized in <xref ref-type="table" rid="mpv17-mtdep.T.clinical_manifestations_of">Table 2</xref>.</p>
          <table-wrap id="mpv17-mtdep.T.clinical_manifestations_of" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Clinical Manifestations of <italic toggle="yes">MPV17</italic>-Related Hepatocerebral mtDNA Depletion Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Clinical Manifestations</th>
                  <th id="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Frequency</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><bold>Hepatic</bold>
<list list-type="bullet"><list-item><p>Liver dysfunction</p></list-item><list-item><p>Liver failure</p></list-item><list-item><p>Hepatomegaly</p></list-item><list-item><p>Liver cirrhosis</p></list-item><list-item><p>Hepatocellular cancer</p></list-item></list></td>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><bold>31/31 (100%)</bold>
<list list-type="bullet"><list-item><p>31/31 (100%)</p></list-item><list-item><p>28/31 (90%)</p></list-item><list-item><p>14/29 (48%)</p></list-item><list-item><p>7/29 (24%)</p></list-item><list-item><p>2/31 (6%)</p></list-item></list></td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><bold>Neurologic</bold>
<list list-type="bullet"><list-item><p>Developmental delay</p></list-item><list-item><p>Hypotonia, muscle weakness</p></list-item><list-item><p>White&#x000a0;matter&#x000a0;abnormalities&#x000a0;in&#x000a0;brain&#x000a0;MRI</p></list-item><list-item><p>Peripheral neuropathy</p></list-item><list-item><p>Seizures</p></list-item><list-item><p>Microcephaly</p></list-item><list-item><p>Ataxia</p></list-item></list></td>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><bold>26/29 (90%)</bold>
<list list-type="bullet"><list-item><p>24/29 (83%)</p></list-item><list-item><p>19/29 (66%)</p></list-item><list-item><p>10/29 (34%)</p></list-item><list-item><p>8/29 (28%)</p></list-item><list-item><p>3/29 (10%)</p></list-item><list-item><p>2/29 (7%)</p></list-item><list-item><p>2/29 (7%)</p></list-item></list></td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Failure to thrive</bold>
                  </td>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <bold>26/29 (90%)</bold>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><bold>Metabolic</bold>
<list list-type="bullet"><list-item><p>Lactic acidosis</p></list-item><list-item><p>Hypoglycemia</p></list-item></list></td>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><bold>23/27 (85%)</bold>
<list list-type="bullet"><list-item><p>20/27 (74%)</p></list-item><list-item><p>13/27 (48%)</p></list-item></list></td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><bold>Other manifestations</bold>
<list list-type="bullet"><list-item><p>Renal tubulopathy</p></list-item><list-item><p>Gastroesophageal reflux</p></list-item><list-item><p>Vomiting and/or diarrhea</p></list-item><list-item><p>Corneal anesthesia and ulcers</p></list-item><list-item><p>Hypoparathyroidism</p></list-item></list></td>
                  <td headers="hd_h_mpv17-mtdep.T.clinical_manifestations_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><bold>&#x02014;</bold>
<list list-type="bullet"><list-item><p>3/29 (10%)</p></list-item><list-item><p>3/29 (10%)</p></list-item><list-item><p>3/29 (10%)</p></list-item><list-item><p>3/29 (10%)</p></list-item><list-item><p>2/29 (7%)</p></list-item></list></td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p><bold>Liver dysfunction</bold>. All reported individuals with <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome came to medical attention in infancy with manifestations of liver dysfunction including jaundice, cholestasis, elevated transaminases and gamma-glutamyl transpeptidase (GGT), hyperbilirubinemia, and coagulopathy. Approximately half were reported to have hepatomegaly.</p>
          <p>In 90% of affected individuals liver disease progressed to liver failure typically during infancy or early childhood. About a quarter were reported to have liver cirrhosis typically in early childhood; two developed hepatocellular carcinoma at ages seven and 11 years [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
          <p>Liver biopsy may show cholestasis and cirrhosis.</p>
          <p><bold>Neurologic manifestations.</bold> The vast majority of affected individuals exhibited neurologic manifestations, including developmental delay (~85%), hypotonia and muscle weakness (~65%), and motor and sensory peripheral neuropathy (~30%). Very few affected individuals were reported to have normal psychomotor development; the majority was reported to have a variable degree of developmental delay. Some affected individuals presented with psychomotor delays during early infancy while others had normal development early in life followed by loss of motor and cognitive abilities later in infancy or early childhood. Peripheral neuropathy typically manifests in early childhood with muscle weakness and wasting, decreased reflexes, and loss of sensation in the hands and feet [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.wong.2007.1218">Wong et al 2007</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.navarrosastre.2008.234">Navarro-Sastre et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2008.1108">Spinazzola et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.kaji.2009.292">Kaji et al 2009</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.parini.2009.215">Parini et al 2009</xref>].</p>
          <p>Less frequent neurologic manifestations include epilepsy, ataxia, dystonia, microcephaly, cerebrovascular infarction, and subdural hematoma.</p>
          <p>Brain MRI abnormalities were reported in approximately one third of affected individuals, with white matter abnormalities (leukoencephalopathy) being the most common. Two individuals have been reported with T<sub>2</sub> hyperintensities within the reticular formation of the lower dorsal brain stem and the reticulospinal tracts of the cervicomedullary junction [<xref ref-type="bibr" rid="mpv17-mtdep.REF.merkle.2012.e34">Merkle et al 2012</xref>].</p>
          <p><bold>Failure to thrive</bold> is one of the common manifestations, although some children have normal growth, especially early in the course of the disease.</p>
          <p><bold>Metabolic derangements</bold> occur in the vast majority with lactic acidosis occurring in approximately 75% and early-onset hypoglycemia in approximately 50%. Hypoglycemia typically presents during the first six months of life and can be associated with lethargy, apnea, and/or seizures. Lactic acidosis is a biochemical finding with mild to moderate elevation of lactate (3-9 mmol/L) [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.wong.2007.1218">Wong et al 2007</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.navarrosastre.2008.234">Navarro-Sastre et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2008.1108">Spinazzola et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.kaji.2009.292">Kaji et al 2009</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.parini.2009.215">Parini et al 2009</xref>].</p>
          <p><bold>Less frequent manifestations</bold> include renal tubulopathy, hypoparathyroidism, and gastrointestinal dysmotility manifest as gastroesophageal reflux, cyclic vomiting, and/or diarrhea.</p>
          <p>Corneal anesthesia and ulcers were reported in three individuals considered to have Navajo neurohepatopathy who were homozygous for the pathogenic variant p.Arg50Gln.</p>
          <p><bold>Prognosis.</bold> Liver disease typically progresses to liver failure in affected children. Liver transplantation, the only treatment option for liver failure, has been performed in about one third of affected children. The outcome has not been satisfactory: half of the children undergoing transplantation died during the post-transplantation period because of multi-organ failure and/or sepsis.</p>
          <p>Approximately half of affected children reported did not undergo liver transplantation and died because of progressive liver failure, the majority during infancy or early childhood. Three affected individuals homozygous for p.Arg50Gln died in their second decade.</p>
          <p>Only four children were reported to survive without liver transplantation, the oldest of whom is age 13 years. Two of the four (including the 13-year old) are homozygous for the p.Arg50Gln pathogenic variant, indicating a better prognosis associated with p.Arg50Gln homozygosity (see <xref ref-type="sec" rid="mpv17-mtdep.GenotypePhenotype_Correlatio">Genotype-Phenotype Correlations</xref>; <xref ref-type="table" rid="mpv17-mtdep.T.outcome_of_children_with_m">Table 3</xref>)</p>
          <p>Two affected individuals developed hepatocellular carcinoma.</p>
          <table-wrap id="mpv17-mtdep.T.outcome_of_children_with_m" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Outcome of Children with <italic toggle="yes">MPV17</italic>-Related Hepatocerebral mtDNA Depletion Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Liver Transplant?</th>
                  <th id="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Outcome</th>
                  <th id="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Frequency</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>No (21/31)</bold>
                  </td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Death</td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">In infancy or early childhood</td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">14/31 (45%)</td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">In the second decade</td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3/31 (10%)</td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Survival</td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4/31 (13%)</td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Yes (10/31)</bold>
                  </td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" valign="middle" colspan="2" align="left" rowspan="1">Death</td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5/31 (16%)</td>
                </tr>
                <tr>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_2" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Survival</td>
                  <td headers="hd_h_mpv17-mtdep.T.outcome_of_children_with_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5/31 (16%)</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="mpv17-mtdep.GenotypePhenotype_Correlatio">
          <title>Genotype-Phenotype Correlations</title>
          <p>To date, the p.Arg50Gln pathogenic variant has only been reported in the homozygous state in Navajo neurohepatopathy, which has the manifestations of <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome as well as corneal anesthesia, ulceration, and scarring.</p>
          <p>In contrast to most <italic toggle="yes">MPV17</italic> pathogenic variants that are associated with death in infancy or early childhood, the p.Arg50Gln variant is associated with longer survival, suggesting that this is a hypomorphic variant.</p>
          <p>Homozygosity for p.Arg50Gln has been reported in ten children, five of whom died, typically in the second decade of life. Liver failure and death were reported in an infant homozygous for the p.Arg50Gln variant whose mtDNA copy number in liver was very low (3%) [<xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2006.570">Spinazzola et al 2006</xref>], whereas children homozygous for the p.Arg50Gln variant who survived longer have a relatively higher mtDNA copy number (10%-20%), suggesting that the degree of mtDNA depletion in the liver correlates with outcome in children homozygous for the p.Arg50Gln variant [<xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
          <p>The other <italic toggle="yes">MPV17</italic> pathogenic variants have been associated with a lower mtDNA copy number than those associated with the p.Arg50Gln variant and death in infancy or early childhood if not treated by liver transplantation [<xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
          <p>Liver transplantation was performed in ten children, five of whom survived the post-transplant period. Of the five survivors, three are homozygous for p.Arg50Gln pathogenic variant, indicating a relatively better response to liver transplantation with this genotype [<xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
        </sec>
        <sec id="mpv17-mtdep.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome is unknown but likely to be very rare, with only 31 affected individuals being reported to date. Seven of the 31 are of Navajo ancestry.</p>
        </sec>
      </sec>
      <sec id="mpv17-mtdep.Genetically_Related_Allelic">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are associated with mutation of <italic toggle="yes">MPV17.</italic></p>
      </sec>
      <sec id="mpv17-mtdep.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Mitochondrial disorders are caused by defects in mitochondrial DNA (mtDNA) or nuclear genes involved in mitochondrial biogenesis and function. Defects in nuclear genes involved in the maintenance of mtDNA integrity can be associated with large-scale rearrangements of mtDNA (mtDNA multiple deletion syndromes) (see <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Mitochondrial DNA Deletion Syndromes</related-object>) or with reduction in the mtDNA content (mtDNA depletion syndromes).</p>
        <p>Mitochondrial DNA depletion syndromes are phenotypically heterogeneous and may affect either a specific organ or a combination of organs, including muscle, liver, brain, and kidney. Clinically, mtDNA depletion syndromes are classified as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurogastrointestinal encephalopathy associated with pathogenic variants in <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter"><italic toggle="yes">TYMP</italic></related-object> (encoding thymidine phosphorylase) or <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic></related-object> (encoding DNA polymerase gamma);</p>
          </list-item>
          <list-item>
            <p>Myopathy associated with pathogenic variants in <related-object link-type="booklink" source-id="gene" document-id="tk2-mtddepl" document-type="chapter"><italic toggle="yes">TK2</italic></related-object> (encoding thymidine kinase 2);</p>
          </list-item>
          <list-item>
            <p>Encephalomyopathy associated with pathogenic variants in <related-object link-type="booklink" source-id="gene" document-id="sucla2-def" document-type="chapter"><italic toggle="yes">SUCLA2</italic></related-object> (encoding ATP-dependent succinyl CoA synthase), <related-object link-type="booklink" source-id="gene" document-id="suclg1-mtddepl" document-type="chapter"><italic toggle="yes">SUCLG1</italic></related-object> (encoding GTP-dependent succinyl CoA synthase), or <related-object link-type="booklink" source-id="gene" document-id="rrm2b-mtddepl" document-type="chapter"><italic toggle="yes">RRM2B</italic></related-object> (encoding p53-induced ribonucleotide reductase B subunit);</p>
          </list-item>
          <list-item>
            <p>Hepatocerebral form associated with pathogenic variants in <italic toggle="yes">TWNK</italic> (encoding Twinkle), <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic></related-object> (encoding DNA polymerase gamma), <related-object link-type="booklink" source-id="gene" document-id="dguok-mtddepl" document-type="chapter"><italic toggle="yes">DGUOK</italic></related-object> (encoding deoxyguanosine kinase), or <italic toggle="yes">MPV17</italic>.</p>
          </list-item>
        </list>
        <p><italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome needs to be differentiated from other types of hepatocerebral mtDNA depletion syndromes associated with biallelic pathogenic variants in <italic toggle="yes">DGUOK, TWNK</italic>, or <italic toggle="yes">POLG</italic>. In addition, pathogenic variants in <italic toggle="yes">BCS1L</italic> (encoding a mitochondrial protein involved in complex III assembly) and <italic toggle="yes">SCO1</italic> (encoding a mitochondrial protein involved in complex IV assembly) have been associated with encephalopathy and hepatic dysfunction [<xref ref-type="bibr" rid="mpv17-mtdep.REF.valnot.2000.1104">Valnot et al 2000</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.visap__.2002.863">Visap&#x000e4;&#x000e4; et al 2002</xref>].</p>
        <p>In <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome, liver involvement appears early in the course of the disease, unlike most of the other multisystem mitochondrial disorders with prominent neuromuscular involvement, in which liver complications are more commonly a late feature. In contrast to other mtDNA depletion syndromes, neurologic involvement in <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome is generally mild at the onset of disease [<xref ref-type="bibr" rid="mpv17-mtdep.REF.wong.2007.1218">Wong et al 2007</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>]. However, <related-object link-type="booklink" source-id="gene" document-id="dguok-mtddepl" document-type="chapter"><italic toggle="yes">DGUOK</italic>-related hepatocerebral mtDNA depletion syndrome</related-object> may also present as isolated liver disease without neuromuscular involvement [<xref ref-type="bibr" rid="mpv17-mtdep.REF.freisinger.2006.1129">Freisinger et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.dimmock.2008.330">Dimmock et al 2008</xref>].</p>
        <p>Infantile liver failure is also a feature of the disorders caused by pathogenic variants in <italic toggle="yes">TRMU</italic> (encoding mitochondria tRNA-specific 2-thiouridylase 1) and <italic toggle="yes">GFM1</italic> (encoding mitochondrial elongation factor G); mtDNA depletion is not a feature in these disorders [<xref ref-type="bibr" rid="mpv17-mtdep.REF.coenen.2004.2080">Coenen et al 2004</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.zeharia.2009.401">Zeharia et al 2009</xref>].</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS603041">Mitochondrial DNA depletion syndrome: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="mpv17-mtdep.Management">
        <title>Management</title>
        <sec id="mpv17-mtdep.Evaluations_Following_Initia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome, the following evaluations are recommended.</p>
          <list list-type="bullet">
            <list-item>
              <p>Hepatic</p>
              <list list-type="bullet">
                <list-item>
                  <p>Liver function including liver transaminases (ALT and AST), GGT, albumin, total and direct bilirubin, and coagulation profile (PT and PTT)</p>
                </list-item>
                <list-item>
                  <p>Ultrasound examination to assess liver size and texture, and for the presence of masses</p>
                </list-item>
                <list-item>
                  <p>Alpha fetoprotein (AFP) to screen for hepatocellular carcinoma</p>
                </list-item>
                <list-item>
                  <p>Hepatology/liver transplantation consultation</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Neurologic</p>
              <list list-type="bullet">
                <list-item>
                  <p>Developmental evaluation</p>
                </list-item>
                <list-item>
                  <p>Neurologic consultation and comprehensive neurologic examination</p>
                </list-item>
                <list-item>
                  <p>Brain MRI to assess white matter and other abnormalities. The brain MRI findings can establish the degree of central nervous system involvement and serve as a baseline for monitoring the progression of the neurologic disease.</p>
                </list-item>
                <list-item>
                  <p>Nerve conduction velocity (NCV) to assess peripheral neuropathy. NCV can establish the degree of the peripheral nervous system involvement and serve as a baseline for monitoring the progression of the neurologic disease.</p>
                </list-item>
                <list-item>
                  <p>EEG if seizures are suspected</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Nutritional evaluation</p>
            </list-item>
            <list-item>
              <p>Plasma lactate and glucose concentration</p>
            </list-item>
            <list-item>
              <p>Urinalysis and amino acids to assess for renal tubulopathy</p>
            </list-item>
            <list-item>
              <p>Gastrointestinal consultation if gastrointestinal dysmotility is present</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic examination to assess corneal sensation and possible corneal ulcers/scaring</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpv17-mtdep.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management should involve a multidisciplinary team including specialists in hepatology, neurology, nutrition, clinical genetics, and child development. Treatment of <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome remains unsatisfactory with a mortality rate higher than 50% (see <xref ref-type="sec" rid="mpv17-mtdep.Clinical_Description">Clinical Description</xref>, <bold>Prognosis</bold>).</p>
          <p>Nutritional support should be provided by a dietitian experienced in managing children with liver diseases.</p>
          <p>Prevention of hypoglycemia requires frequent feeds and avoidance of fasting. Uncooked cornstarch (1-2 grams/kg/dose) can be used to manage hypoglycemia, and it may slow but not stop the progression of the liver disease [<xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2008.1108">Spinazzola et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.parini.2009.215">Parini et al 2009</xref>].</p>
          <p><bold>Liver transplantation.</bold> Although liver transplantation remains the only treatment option for liver failure, liver transplantation in mitochondrial hepatopathy is controversial, largely because of the multisystemic involvement. Liver transplantation has been performed in about one third of affected children; the outcome has not been satisfactory, with half of the transplanted children dying in the post-transplantation period because of multi-organ failure and/or sepsis (see <xref ref-type="sec" rid="mpv17-mtdep.Clinical_Description">Clinical Description</xref>, <bold>Prognosis</bold>).</p>
          <p><bold>Hepatocellular carcinoma.</bold> The two children reported with hepatocellular carcinoma (HCC) were treated by liver transplantation. Screening for HCC using periodic hepatic ultrasound examination and serum alpha fetoprotein concentration potentially could result in earlier diagnosis, enabling liver transplantation before metastasis or local invasion occurs.</p>
        </sec>
        <sec id="mpv17-mtdep.Prevention_of_Secondary_Comp">
          <title>Prevention of Secondary Complications</title>
          <p>Nutritional deficiencies, for example of fat-soluble vitamins, can be prevented by ensuring adequate intake and frequent assessment by a dietitian experienced in managing children with liver diseases.</p>
        </sec>
        <sec id="mpv17-mtdep.Surveillance">
          <title>Surveillance</title>
          <p>No clinical guidelines for surveillance are available.</p>
          <p>The following evaluations are suggested, with frequency varying according to the severity of the condition:</p>
          <list list-type="bullet">
            <list-item>
              <p>Liver function tests including liver transaminases (ALT and AST), GGT, albumin, total and direct bilirubin, and coagulation profile (PT and PTT)</p>
            </list-item>
            <list-item>
              <p>Hepatic ultrasound examination to screen for liver masses that might suggest HCC</p>
            </list-item>
            <list-item>
              <p>Serum alpha fetoprotein (AFP) concentration</p>
            </list-item>
            <list-item>
              <p>Developmental evaluation</p>
            </list-item>
            <list-item>
              <p>Neurologic assessment</p>
            </list-item>
            <list-item>
              <p>Nutritional assessment</p>
            </list-item>
            <list-item>
              <p>Urinalysis and urine amino acids to assess for renal tubulopathy</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic examination</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpv17-mtdep.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Prolonged fasting can lead to hypoglycemia and should be avoided.</p>
        </sec>
        <sec id="mpv17-mtdep.Evaluation_of_Relatives_at_R">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="mpv17-mtdep.Related_Genetic_Counseling_I">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="mpv17-mtdep.Therapies_Under_Investigatio">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="mpv17-mtdep.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="mpv17-mtdep.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="mpv17-mtdep.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutated allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> To date no affected individuals have reproduced; therefore, fertility is not yet known.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="mpv17-mtdep.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="mpv17-mtdep.Related_Genetic_Counseling_I">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="mpv17-mtdep.Prenatal_Testing_and_Preimpl">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">MPV17</italic> pathogenic variants have been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for <italic toggle="yes">MPV17</italic>-related hepatocerebral mtDNA depletion syndrome are possible.</p>
        </sec>
      </sec>
      <sec id="mpv17-mtdep.Resources">
        <title>Resources</title>
      </sec>
      <sec id="mpv17-mtdep.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">MPV17</italic> spans 13.6 kb and comprises eight exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="mpv17-mtdep" object-id="mpv17-mtdep.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> To date, 20 different <italic toggle="yes">MPV17</italic> pathogenic variants have been reported in children with hepatocerebral mtDNA depletion (<xref ref-type="table" rid="mpv17-mtdep.T.mpv17_pathogenic_variants">Table 4</xref>). About half of those variants are missense and the remaining half includes nonsense and splice site variants and small deletions and insertions. A large deletion spanning exon 8 has also been reported.</p>
        <list list-type="bullet">
          <list-item>
            <p>The most common pathogenic variant, p.Arg50Gln, has been identified in seven families.</p>
          </list-item>
          <list-item>
            <p>Each of four pathogenic variants (p.Arg50Trp, p.Lys88del, p.Leu91del, and the 1.57-kb deletion spanning the last exon) has been observed in two families.</p>
          </list-item>
          <list-item>
            <p>All other pathogenic variants are private [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2006.570">Spinazzola et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.wong.2007.1218">Wong et al 2007</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.navarrosastre.2008.234">Navarro-Sastre et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2008.1108">Spinazzola et al 2008</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.kaji.2009.292">Kaji et al 2009</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.parini.2009.215">Parini et al 2009</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.elhattab.2010.300">El-Hattab et al 2010</xref>].</p>
          </list-item>
        </list>
        <table-wrap id="mpv17-mtdep.T.mpv17_pathogenic_variants" orientation="portrait" position="anchor">
          <label>Table 4. </label>
          <caption>
            <p><italic toggle="yes">MPV17</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type of Variant</th>
                <th id="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" rowspan="9" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Missense</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.70G&#x0003e;T</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly24Trp</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_4" rowspan="20" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_002437.4">NM_002437.4</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_002428.1">NP_002428.1</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.148C&#x0003e;T</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg50Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.149G&#x0003e;A</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg50Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.262A&#x0003e;G</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Lys88Glu</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.280G&#x0003e;C</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly94Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.293C&#x0003e;T</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro98Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.485C&#x0003e;A</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala162Asp</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.498C&#x0003e;A</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn166Lys</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.509C&#x0003e;T</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser170Phe</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Nonsense</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.206G&#x0003e;A</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp69Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.359G&#x0003e;A</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp120Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>In-frame deletion</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.234_242del9</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly79_Thr81del</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.263_265del3</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Lys88del</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.271_273del3</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu91del</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Frame shift deletion</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.116-141del26</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg41ProfsTer63</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Insertion</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.22_23insC</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln8ProfsTer24</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.451_452insC</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu151ProfsTer39</td>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Splicing site</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.70+5G&#x0003e;A</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">c.186+2T&#x0003e;C</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Large deletion</bold>
                </td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.57-kb deletion spanning exon 8</td>
                <td headers="hd_h_mpv17-mtdep.T.mpv17_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">MPV17</italic> encodes the MPV17 protein, an inner mitochondrial membrane protein that is predicted to contain four transmembrane segments (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uniprot.org/uniprot/P39210">uniprot.org</ext-link>).</p>
        <p>The function of the MPV17 protein and its role in the pathogenesis of mtDNA depletion syndrome are as yet unknown. It has been suggested that MPV17 plays a role in controlling mtDNA maintenance and oxidative phosphorylation activity in mammals and yeast [<xref ref-type="bibr" rid="mpv17-mtdep.REF.karadimas.2006.544">Karadimas et al 2006</xref>, <xref ref-type="bibr" rid="mpv17-mtdep.REF.dallabona.2010.1098">Dallabona et al 2010</xref>].</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">MPV17</italic> pathogenic variants result in dysfunctional MPV17 protein resulting in impaired mtDNA maintenance leading to mtDNA depletion. Individuals with biallelic <italic toggle="yes">MPV17</italic> pathogenic variants have a severe decrease in mtDNA content, leading to insufficient production of respiratory chain components, resulting in impaired energy production and organ dysfunction [<xref ref-type="bibr" rid="mpv17-mtdep.REF.spinazzola.2006.570">Spinazzola et al 2006</xref>].</p>
      </sec>
      <sec id="mpv17-mtdep.References">
        <title>References</title>
        <sec id="mpv17-mtdep.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="mpv17-mtdep.Literature_Cited.reflist0">
            <ref id="mpv17-mtdep.REF.coenen.2004.2080">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coenen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonicka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugalde</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasarman</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heister</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newbold</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trijbels</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Heuvel</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoubridge</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency.</article-title>
                <source>N Engl J Med</source>
                <volume>351</volume>
                <fpage>2080</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15537906</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.dimmock.2008.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dimmock</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrozzo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shieh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Truong</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sifry-Platt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucioli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wierenga</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lipson</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase.</article-title>
                <source>Hum Mutat</source>
                <volume>29</volume>
                <fpage>330</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">18205204</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.dallabona.2010.1098">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dallabona</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsano</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arzuffi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghezzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnini</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator.</article-title>
                <source>Hum Mol Genet</source>
                <volume>19</volume>
                <fpage>1098</fpage>
                <lpage>107</lpage>
                <pub-id pub-id-type="pmid">20042463</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.dimmock.2010.1119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dimmock</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Quantitative evaluation of the mitochondrial DNA depletion syndrome.</article-title>
                <source>Clin Chem</source>
                <volume>56</volume>
                <fpage>1119</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">20448188</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.elhattab.2010.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>El-Hattab</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel mutations.</article-title>
                <source>Mol Genet Metab</source>
                <volume>99</volume>
                <fpage>300</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20074988</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.freisinger.2006.1129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000fc;tterer</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lankes</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gempel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spalinger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoerbe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwantes</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burdelski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Setzer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>UA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horv&#x000e1;th</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hepatocerebral mitochondrial DNA depletion syndrome caused by deoxyguanosine kinase (DGUOK) mutations.</article-title>
                <source>Arch Neurol</source>
                <volume>63</volume>
                <fpage>1129</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">16908739</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.kaji.2009.292">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaji</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murayama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagata</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagasaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takayanagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohtake</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwasa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishiyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okazaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harashima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eitoku</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsushita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katayama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugimoto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujimoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanzaki</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiraki</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II.</article-title>
                <source>Mol Genet Metab</source>
                <volume>97</volume>
                <fpage>292</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19520594</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.karadimas.2006.544">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Karadimas</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vu</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holve</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chronopoulou</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinzii</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnsen</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurth</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palenzuela</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonilla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vivo</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Navajo neurohepatopathy is caused by a mutation in the MPV17 gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>79</volume>
                <fpage>544</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16909392</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.merkle.2012.e34">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merkle</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nascene</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKinney</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>MR imaging findings in the reticular formation in siblings with MPV17-related mitochondrial depletion syndrome.</article-title>
                <source>AJNR Am J Neuroradiol.</source>
                <volume>33</volume>
                <fpage>E34</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21511859</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.navarrosastre.2008.234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Navarro-Sastre</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n-Hern&#x000e1;ndez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quintana</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Las Heras</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lluch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mu&#x000f1;oz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>del Hoyo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gort</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briones</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Lethal hepatopathy and leukodystrophy caused by a novel mutation in MPV17 gene: description of an alternative MPV17 spliced form.</article-title>
                <source>Mol Genet Metab</source>
                <volume>94</volume>
                <fpage>234</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18329934</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.parini.2009.215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furlan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spinazzola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uziel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Concolino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corbetta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nebbia</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maggioni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients.</article-title>
                <source>J Hepatol</source>
                <volume>50</volume>
                <fpage>215</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">19012992</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.spinazzola.2008.1108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spinazzola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akman</surname>
                    <given-names>OH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsiakas</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karadimas</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Mauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations.</article-title>
                <source>Arch Neurol</source>
                <volume>65</volume>
                <fpage>1108</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">18695062</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.spinazzola.2006.570">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spinazzola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viscomi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Vizarra</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Adamo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsano</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiher</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mootha</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion.</article-title>
                <source>Nat Genet</source>
                <volume>38</volume>
                <fpage>570</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16582910</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.valnot.2000.1104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Valnot</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osmond</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gigarel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehaye</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amiel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnefont</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rustin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy.</article-title>
                <source>Am J Hum Genet</source>
                <volume>67</volume>
                <fpage>1104</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11013136</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.visap__.2002.863">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visap&#x000e4;&#x000e4;</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fellman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vesa</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasvarma</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutton</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Payne</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makarow</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Coster</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltonen</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L.</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>863</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">12215968</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.wong.2007.1218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunetti-Pierri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazigi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bove</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahms</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puchowicz</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez-Gomez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Truong</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppel</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldwin</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leslie</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boles</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerr</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy.</article-title>
                <source>Hepatology</source>
                <volume>46</volume>
                <fpage>1218</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">17694548</pub-id>
              </element-citation>
            </ref>
            <ref id="mpv17-mtdep.REF.zeharia.2009.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zeharia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pappo</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mager-Heckel</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beinat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karicheva</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ofek</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marom</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarassov</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Acute infantile liver failure due to mutations in the TRMU gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>85</volume>
                <fpage>401</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19732863</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="mpv17-mtdep.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="mpv17-mtdep.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 May 2012 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>27 February 2012 (aeh) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
